Cost-effectiveness of drotrecogin alfa (activated).
D003362:Cost-Benefit Analysis; D003422:Critical Care / Q000191:economics; D017048:Health Care Costs; D017721:Hospital Costs; D006801:Humans; D007362:Intensive Care Units / Q000191:economics; D011486:Protein C / Q000191:economics* / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D011994:Recombinant Proteins / Q000191:economics* / Q000627:therapeutic use; D018805:Sepsis / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics
D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated